跳转至内容
Merck

Y0001586

盐酸托莫西汀 盐酸盐

European Pharmacopoeia (EP) Reference Standard

别名:

R)-托莫西汀 盐酸盐, 盐酸托莫西汀 盐酸盐, (R)-N-甲基-γ-(2-甲基­苯氧基)苯丙胺 盐酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H21NO · HCl
CAS号:
分子量:
291.82
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

atomoxetine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

InChI 密鑰

LUCXVPAZUDVVBT-UNTBIKODSA-N

基因資訊

human ... SLC6A2(6530)

正在寻找类似产品? 访问 产品对比指南

一般說明

本品按现行药典规定交付。该产品的所有支持信息,包括SDS和任何产品信息宣传页均由药典发行机构制定并发布。如需更多信息和支持,请见现行药典的网站。

應用

盐酸阿托西汀EP参考标准品的预期用途是欧洲药典规定的实验室测试。

生化/生理作用

去甲肾上腺素摄取阻滞剂。

包裝

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他說明

可能适用相应的销售限制。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Irene Joy I Dela Peña et al.
Progress in neuro-psychopharmacology & biological psychiatry, 88, 311-319 (2018-08-21)
Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous neurodevelopmental disorder characterized by varying levels of hyperactivity, inattention, and impulsivity. Patients with ADHD are often classified as (1) predominantly hyperactive-impulsive, (2) predominantly inattentive, and (3) combined type. There is a growing interest in
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G, et al.
European Neuropsychopharmacology, 19(11), 822-834 (2009)
METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ATOMOXETINE HYDROCHLORIDE IN BULK AND CAPSULE DOSAGE FORM BY RP-HPLC.
Swathi G, et al.
World Journal of Pharmacy and Pharmaceutical Sciences (2015)
Dylan Chou et al.
Experimental neurology, 255, 19-29 (2014-03-04)
Fear conditioning in animals has been used extensively to model clinical anxiety disorders. While individual animals exhibit marked differences in their propensity to undergo fear conditioning, the physiologically relevant mediators have not yet been fully characterized. Here, we demonstrate that
Atomoxetine-induced wake-time teeth clenching and sleep bruxism in a child patient.
Kayhan Bahali et al.
European child & adolescent psychiatry, 23(12), 1233-1235 (2014-08-28)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门